Citius Oncology (CTOR) Other Non-Current Assets (2021 - 2026)

Citius Oncology (CTOR) has reported Other Non-Current Assets for 6 consecutive years, with $69.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other Non-Current Assets fell 5.47% year-over-year to $69.4 million in Q2 2026; TTM through Jun 2026 was $69.4 million, a 5.47% decrease from a year earlier, with the FY2025 full-year figure at $73.4 million, changed 0.0% from the prior year.
• Other Non-Current Assets was $69.4 million for Q2 2026 at Citius Oncology, down from $71.3 million in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $73.4 million in Q3 2024 and troughed at $256745.0 in Q3 2022.
• A 5-year average of $62.1 million and a median of $73.1 million in 2024 frame the typical range for Other Non-Current Assets.
• Across the five-year window, Other Non-Current Assets surged 15479.66% in 2023 and slipped 5.47% in 2026, its largest moves.
• Over 5 years, Other Non-Current Assets stood at $256745.0 in 2022, then surged by 15479.66% to $40.0 million in 2023, then soared by 83.5% to $73.4 million in 2024, then retreated by 0.78% to $72.8 million in 2025, then dropped by 4.72% to $69.4 million in 2026.
• The last three Other Non-Current Assets figures came in at $69.4 million (Q2 2026), $71.3 million (Q1 2026), and $72.8 million (Q4 2025), per Business Quant data.